BiomeBank is a clinical‑stage biotechnology company that secured world‑first regulatory approval of a donor‑derived microbiome drug product and is commercializing supply of that therapy. The company received a $10 million capital raise to scale its GMP manufacturing and increase global supply. BiomeBank plans to reformulate the approved product into a freeze‑dried, encapsulated oral therapy and to advance drug discovery for defined, cultured "second‑generation" microbiome therapies. Its pipeline includes BB265, a cultured therapy for ulcerative colitis slated to enter the company’s first human clinical trial. BiomeBank leverages a large culture collection of bacterial strains and a platform combining machine learning and microbiology, and has announced research collaborations with the Hudson Institute and RMIT. The company has grown headcount from nine to twenty‑two with further growth forecast for 2023.

Total raised

$10M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2022